inclusion criteria: 1. written informed consent of the patient to participate in the study. 2. patients aged 18-75 years inclusive. 3. covid-19 diagnosis based on laboratory confirmation of sars-cov-2 virus, conducted within 3 days prior to the first dose of the drug. determination of sars-cov-2 virus by polymerase chain reaction (pcr) or other method regulated by the actual clinical recommendations is acceptable. 4. patients with a mild course of covid-19 - presence of at least 2 criteria: spo2 ≥ 95% (mandatory criterion), body temperature ˂ 38°c, respiratory rate (rr) ≤ 22/min. 5. duration of illness not more than 3 full days from the onset of one or more of the following symptoms until the first dose of study drug: elevated body temperature; dry cough or cough with small amount of sputum; shortness of breath; myalgia; fatigue; feeling of stuffiness in the chest; sore throat; nasal congestion/rhinorrhea; headache; feeling of heat or fever; decreased sense of smell and/or taste. 6. presence of at least two symptoms on the covid-19 core symptom rating scale with a score of 2 or more. 7. women only: negative pregnancy test result. the pregnancy test need not be performed on women who are not fertile: women who are menopausal (defined as not menstruating for at least two years or more) or who have had surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation) or have a clinical diagnosis of infertility. the presence of surgical sterilization and infertility is evaluated on the patient's word or with a document confirming this condition. 8. women with preserved reproductive potential and men whose partners have preserved reproductive potential agree to abstain from sexual intercourse for the duration of the study. 9. patients who are able to understand and comply with the treatment and procedures of the study.

inclusion criteria: 1. written informed consent of the patient to participate in the study. 2. patients aged 18-75 years inclusive. 3. covid-19 diagnosis based on laboratory confirmation of sars-cov-2 virus, conducted within 3 days prior to the first dose of the drug. determination of sars-cov-2 virus by polymerase chain reaction (pcr) or other method regulated by the actual clinical recommendations is acceptable. 4. patients with a mild course of covid-19 - presence of at least 2 criteria: spo2 ≥ 95% (mandatory criterion), body temperature ˂ 38°c, respiratory rate (rr) ≤ 22/min. 5. duration of illness not more than 3 full days from the onset of one or more of the following symptoms until the first dose of study drug: elevated body temperature; dry cough or cough with small amount of sputum; shortness of breath; myalgia; fatigue; feeling of stuffiness in the chest; sore throat; nasal congestion/rhinorrhea; headache; feeling of heat or fever; decreased sense of smell and/or taste. 6. presence of at least two symptoms on the covid-19 core symptom rating scale with a score of 2 or more. 7. women only: negative pregnancy test result. the pregnancy test need not be performed on women who are not fertile: women who are menopausal (defined as not menstruating for at least two years or more) or who have had surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation) or have a clinical diagnosis of infertility. the presence of surgical sterilization and infertility is evaluated on the patient's word or with a document confirming this condition. 8. women with preserved reproductive potential and men whose partners have preserved reproductive potential agree to abstain from sexual intercourse for the duration of the study. 9. patients who are able to understand and comply with the treatment and procedures of the study.

inclusion criteria: written informed consent of the patient to participate in the study. patients aged 18-75 years inclusive. covid-19 diagnosis based on laboratory confirmation of sars-cov-2 virus, conducted within 3 days prior to the first dose of the drug. determination of sars-cov-2 virus by polymerase chain reaction (pcr) or other method regulated by the actual clinical recommendations is acceptable. patients with a mild course of covid-19 - presence of at least 2 criteria: spo2 ≥ 95% (mandatory criterion), body temperature ˂ 38°c, respiratory rate (rr) ≤ 22/min. duration of illness not more than 3 full days from the onset of one or more of the following symptoms until the first dose of study drug: elevated body temperature; dry cough or cough with small amount of sputum; shortness of breath; myalgia; fatigue; feeling of stuffiness in the chest; sore throat; nasal congestion/rhinorrhea; headache; feeling of heat or fever; decreased sense of smell and/or taste. presence of at least two symptoms on the covid-19 core symptom rating scale with a score of 2 or more. women only: negative pregnancy test result. the pregnancy test need not be performed on women who are not fertile: women who are menopausal (defined as not menstruating for at least two years or more) or who have had surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation) or have a clinical diagnosis of infertility. the presence of surgical sterilization and infertility is evaluated on the patient's word or with a document confirming this condition. women with preserved reproductive potential and men whose partners have preserved reproductive potential agree to abstain from sexual intercourse for the duration of the study. patients who are able to understand and comply with the treatment and procedures of the study.

inclusion criteria: written informed consent of the patient to participate in the study. patients aged 18-75 years inclusive. covid-19 diagnosis based on laboratory confirmation of sars-cov-2 virus, conducted within 3 days prior to the first dose of the drug. determination of sars-cov-2 virus by polymerase chain reaction (pcr) or other method regulated by the actual clinical recommendations is acceptable. patients with a mild course of covid-19 - presence of at least 2 criteria: spo2 ≥ 95% (mandatory criterion), body temperature ˂ 38°c, respiratory rate (rr) ≤ 22/min. duration of illness not more than 3 full days from the onset of one or more of the following symptoms until the first dose of study drug: elevated body temperature; dry cough or cough with small amount of sputum; shortness of breath; myalgia; fatigue; feeling of stuffiness in the chest; sore throat; nasal congestion/rhinorrhea; headache; feeling of heat or fever; decreased sense of smell and/or taste. presence of at least two symptoms on the covid-19 core symptom rating scale with a score of 2 or more. women only: negative pregnancy test result. the pregnancy test need not be performed on women who are not fertile: women who are menopausal (defined as not menstruating for at least two years or more) or who have had surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation) or have a clinical diagnosis of infertility. the presence of surgical sterilization and infertility is evaluated on the patient's word or with a document confirming this condition. women with preserved reproductive potential and men whose partners have preserved reproductive potential agree to abstain from sexual intercourse for the duration of the study. patients who are able to understand and comply with the treatment and procedures of the study.

inclusion criteria: written informed consent of the patient to participate in the study. patients aged 18-75 years inclusive. covid-19 diagnosis based on laboratory confirmation of sars-cov-2 virus, conducted within 3 days prior to the first dose of the drug. determination of sars-cov-2 virus by pcr or other method regulated by the tmr is acceptable. patients with a mild course of covid-19 - presence of at least 2 criteria: spo2 ≥ 95% (mandatory criterion), body temperature ˂ 38°c, resoiratory rate (rr) ≤ 22/min. duration of illness not more than 3 full days from the onset of one or more of the following symptoms until the first dose of study drug: elevated body temperature; dry cough or cough with small amount of sputum; shortness of breath; myalgia; fatigue; feeling of stuffiness in the chest; sore throat; nasal congestion/rinorrhea; headache; feeling of heat or fever; decreased sense of smell and/or taste. presence of at least two symptoms on the covid-19 core symptom rating scale with a score of 2 or more. women only: negative pregnancy test result. the pregnancy test need not be performed on women who are not fertile: women who are menopausal (defined as not menstruating for at least two years or more) or who have had surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation) or have a clinical diagnosis of infertility. the presence of surgical sterilization and infertility is evaluated on the patient's word or with a document confirming this condition. women with preserved reproductive potential and men whose partners have preserved reproductive potential agree to abstain from sexual intercourse for the duration of the study. patients who are able to understand and comply with the treatment and procedures of the study.

inclusion criteria: written informed consent of the patient to participate in the study. patients aged 18-75 years inclusive. covid-19 diagnosis based on laboratory confirmation of sars-cov-2 virus, conducted within 3 days prior to the first dose of the drug. determination of sars-cov-2 virus by pcr or other method regulated by the tmr is acceptable. patients with a mild course of covid-19 - presence of at least 2 criteria: spo2 ≥ 95% (mandatory criterion), body temperature ˂ 38°c, resoiratory rate (rr) ≤ 22/min. duration of illness not more than 3 full days from the onset of one or more of the following symptoms until the first dose of study drug: elevated body temperature; dry cough or cough with small amount of sputum; shortness of breath; myalgia; fatigue; feeling of stuffiness in the chest; sore throat; nasal congestion/rinorrhea; headache; feeling of heat or fever; decreased sense of smell and/or taste. presence of at least two symptoms on the covid-19 core symptom rating scale with a score of 2 or more. women only: negative pregnancy test result. the pregnancy test need not be performed on women who are not fertile: women who are menopausal (defined as not menstruating for at least two years or more) or who have had surgical sterilization (hysterectomy, bilateral oophorectomy, tubal ligation) or have a clinical diagnosis of infertility. the presence of surgical sterilization and infertility is evaluated on the patient's word or with a document confirming this condition. women with preserved reproductive potential and men whose partners have preserved reproductive potential agree to abstain from sexual intercourse for the duration of the study. patients who are able to understand and comply with the treatment and procedures of the study.